Epworth Medical Imaging

Epworth Freemasons
113 Albert Street East Melbourne
Phone 03 9297 8200 | Fax 03 9297 8222
pet@emi.net.au

PET/CT Request/Referral

Patient details

Name .....

DOB / /

Address .....

Medicare No. .....

Telephone .....

Primary Disease site: .....

Histopathology: .....

Chemotherapy: Last: ..... Next: .....

Radiotherapy Planning PET/CT: ☐ Yes ☐ No

Radiotherapy: Last: ..... Next: .....

Hx of melanoma: ☐ Yes ☐ No

(if Y when and site of melanoma): .....

Previous PET scan: ☐ Yes ☐ No Location: .....

Diabetic: ☐ Yes ☐ No

Metformin: ☐ Yes ☐ No

eGFR: ..... Date: .....

Date PET/CT required by: .....

PET/CT Tracer: ☐ F18 FDG ☐ F18 PSMA ☐ 68 Ga DOTA ☐ F18 FET ☐ F18 FES ☐ F18 FBB

Referral Details *Reason for Referral and Clinical History*

Please tick PET indication and diagnostic CT requirements			Diagnostic contrast CT			
Grouping	**Medicare eligible indication** (Medicare criteria on reverse)	**PET**	**Brain**	**Neck**	**Chest, Abdo & Pelvis**	**Other**
Brain	Malignant brain tumour, after definitive therapy (61538)					
	Refractory epilepsy, being evaluated for surgery (61559)					
	Diagnosis of Alzheimer's Disease (AD), clinical evaluation equivocal, 61560/61402 not performed in last 12 months for AD (61560)					
Breast	Staging of locally advanced (Stage III) breast cancer (61524)					
	Evaluation of suspected metastatic breast carcinoma, suitable for active therapy (61525)					
GIT	Colorectal carcinoma, for active therapy (61541)					
	Oesphageal or GEJ carcinoma, staging of proven (61577)					
Gynae	Ovarian carcinoma, following initial therapy, suitable for active therapy (61565)					
	Uterine cervix carcinoma, primary staging (61571)					
	Uterine cervix carcinoma, recurrent cancer for staging (61575)					
Head & neck	Head and Neck cancer, staging of biopsy proven (61598)					
	Head and neck cancer, suspected residual cancer (61604)					
Lung	Solitary pulmonary nodule, staging (61523)					
	Non-small cell lung cancer, staging of proven (61529)					
Lymphoma	HL or NHL, initial staging or untreated (61620)					
	HL or NHL, assess response to first line therapy (61622)					
	HL or NHL, restaging of recurrence (61628)					
	HL or NHL, assess response to second line chemo (61632)					
Melanoma	Melanoma, suspected metastatic or recurrence (61553)					
Metastatic SCC	Metastatic SCC, unknown primary involving cervical nodes (61610)					
Neuroendocrine	68Ga- DOTA . evaluation of gastro-entero-pancreatic neuroendocrine tumour (61647)					
Prostate (PSMA)	Prostate, initial staging of intermediate to high-risk prostate adenocarcinoma (61563)					
	Prostate, restaging with prior locoregional therapy and suitable for active therapy (61564)					
Rare and uncommon Cancer	Rare or uncommon tumours (↓12 cases per 100,000) suitable for active therapy (61612)					
Sarcoma	Sarcoma, initial staging biopsy proven bone or soft tissue excluding GIST (61640)					
	Sarcoma, suspected residual or recurrent tumour excluding GIST (61646)					
	Non-Rebatable indications	**PET**	**Brain**	**Neck**	**Chest, Abdo & Pelvis**	**Other**
Other						

Referring doctor's details

Signature Date

Copy to

Internal use only Y N

Pregnant ☐ ☐

Patient identification verified ☐

Procedure and consent verified ☐

Tech name/position:

.....

.....

Thank you for referring your patient to Epworth Medical Imaging

Epworth Medical Imaging

PET/CT Request/Referral

BREAST		
Staging of locally advanced (Stage III) breast Ca	**61524**	BREAST CANCER, Stage III, Whole body FDG PET study performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy.
Suspected metastatic or recurrent	**61525**	BREAST CANCER, Whole body FDG PET study performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy.
LUNG		
Solitary Pulmonary Nodule	**61523**	SOLITARY PULMONARY NODULE evaluation, Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
Non-Small Cell Lung Cancer – Staging	**61529**	NON-SMALL CELL LUNG CANCER, Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
LYMPHOMA		
HL or NHL, initial staging	**61620**	HL or NHL, Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, assess response to first line therapy	**61622**	HL or NHL, Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, restaging	**61628**	HL or NHL, Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, assess response to second line chemo	**61632**	HL or NHL, Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
HEAD & NECK		
Head and Neck Ca, staging	**61598**	HEAD and NECK CANCER, Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.
Suspected residual Ca	**61604**	HEAD and NECK CANCER, Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.
Metastatic SCC	**61610**	METASTATIC SCC, Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
GASTROINTESTINAL		
Colorectal Carcinoma	**61541**	COLORECTAL CARCINOMA, Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Oesophageal or GEJ carcinoma	**61577**	OESOPHAGEAL or GEJ CARCINOMA, Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.
GYNAECOLOGICAL		
Ovarian carcinoma	**61565**	OVARIAN CARCINOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine cervix carcinoma, primary staging	**61571**	UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Uterine cervix carcinoma, recurrent Ca	**61575**	UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
SARCOMA		
Initial staging	**61640**	SARCOMA, Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Suspected residual or recurrent	**61646**	SARCOMA, Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
PROSTATE		
PSMA initial staging	**61563**	Whole body PSMA PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Medicare benefits are payable for a maximum of one service in the patient's lifetime.
PSMA restaging	**61564**	Whole body PSMA PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who has undergone prior locoregional therapy and is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation. This item can be claimed by patients with a prostate specific antigen (PSA) increase of 2ng/ml above the nadir after radiation therapy; or failure of PSA levels to fall to undetectable levels; or rising PSA serum after a radical prostatectomy. Medicare benefits are payable for a maximum of two services in the patient's lifetime.
BRAIN		
Alzheimer's Disease	**61560**	ALZHEIMER'S DISEASE, FDG PET study of the brain, performed for the diagnosis of (61560 + 56001), if: a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and c) a service to which this item applies has not been performed on the patient in the previous 12 months; and d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer's disease. Applicable not more than 3 times per lifetime
Malignant Brain Tumour	**61538**	MALIGNANT BRAIN TUMOUR, FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
Refractory Epilepsy (evaluated for surgery)	**61559**	REFRACTORY EPILEPSY, FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
MELANOMA		
Melanoma	**61553**	MELANOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
NEUROENDOCRINE		
DOTA (Ga^{68}) for evaluation of NETs	**61647**	^{68}Ga - DOTA, Whole body PET study if: a) a gastro-entero-pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or b) both (i) a surgical amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and (ii) the study is for excluding additional disease sites.
OTHER		
Rare and uncommon cancer	**61612**	Rare and uncommon cancer , Whole body FDG PET study for the initial of eligible cancer types, for a patient who is considered suitable for active therapy, if: a) the eligible cancer type is: (i) a rare or uncommon cancer (less than 12 cases per 100,000 persons per year); and (ii) a typically FDG avid cancer; and b) there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient Applicable once per cancer diagnosis

Epworth Freemasons

113 Albert Street East Melbourne
Phone 03 9297 8200 | Fax 03 9297 8222
pet@emi.net.au

Your doctor has recommended you use Epworth Medical Imaging.
You may choose another provider but please discuss this with your doctor first.